NOX1 and colonic neoplasm: Because both of these two investigational molecules are predicted based on their chemical structures to possess enhanced physical properties compared to either DPI or DTI, we chose to directly evaluate the effects of the new compounds on colon cancer cell growth, cell cycle progression, and NOX1 expression versus established iodonium analogs known to specifically inhibit NOX1 [16].